Xechem Announces date for Annual Stockholders Meeting

ARCHIVED 2002–2016: Originally distributed via the eWire press wire service. Preserved as historical record.

SUBSCRIBE/UNSUBSCRIBE |

Conservation & Wildlife

Corporate Responsibility

Science & Technology

Syndication Partners

**************************************************************************

E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE

**************************************************************************

FOR IMMEDIATE RELEASE

Xechem Announces date for Annual Stockholders Meeting

NEW JERSEY, NEW BRUNSWICK, Oct. 15 -/E-Wire/-- Xechem International, Inc. (OTC BB: ZKEM) announced today that it has set November 20, 2002 as the date for its 2002 Annual Meeting of Stockholders. The Annual Meeting will be held at 10:00 a.m. at the Company's offices located at New Brunswick Technology Center, 100 Jersey Avenue, Building B, Suite 310, New Brunswick, New Jersey. Proxy statements and the Company's Annual Report on Form 10-KSB will be delivered to stockholders beginning on approximately October 17, 2002.

Recently (Xechem press release, August 1, 2002) the Company was granted an exclusive world wide license for a phytopharmaceutical "NIPRISAN" from the National Institute of Pharmaceutical Research and Development (NIPRD), government of Nigeria, for the treatment of Sickle Cell Disease (SCD). Xechem is actively pursuing to submit an Investigational New Drug (IND) Application on this product to the US FDA. Currently there is no such drug for the treatment of this dreadful disease.

Xechem International, Inc., headquartered in New Brunswick, NJ, with subsidiary companies in the USA, India, Nigeria and joint venture partners in both Hong Kong and the Peoples Republic of China, is a biopharmaceutical company of which Xechem, Inc. (a US subsidiary) is engaged in the research, development and production of generic and proprietary drugs from natural sources, specializing in the development of niche-generic, difficult to replicate anticancer, antiviral, including Human Immuno-deficiency Virus (HIV) and antifungal compounds. Xechem is also engaged in the research and development of several novel anti-infectives showing strong and selective efficacy against an array of antibiotic resistant bacterias, including Helicobacter pylori (H. pylori), Vancomycin resistant Enterococcus faecalis (VREF), Methicillin resistant Staphylococcus aureus (MRSA), and other antibiotic resistant Staphylococcus aureus and Candida albicans. The Company also screens extracts and pure compounds from various parts of the world for their therapeutic use.

XetaPharm (another U.S. subsidiary) develops quality controlled nutritional products such as GinkgoOnceÂ®, GinsengOnceÂ®, GarlicOnceÂ®, Gugulonâ¢, VIDA PRASâ¢ and numerous other nutraceutical products, which are under development.

This and past press releases of Xechem International, Inc. are available at Xechem's web site at www.xechem.com.

This news release may contain certain forward-looking statements relating to Xechem's future business performance within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements.

Xechem International, Inc

Ramesh C. Pandey, Ph.D., President & CEO, @

**************************************************************************

To Transmit Your News Over E-Wire, visit http://www.ewire.com or

call 1-[REDACTED-PHONE]. E-Wire Is Broadcast To Millions Of Readers Worldwide

**************************************************************************